Revolutionizing Obesity Treatment with Precision Medicine
May 17, 2024, 4:25 pm
Location: United States, Maryland, Bethesda
Employees: 10001+
Founded date: 1887
Phenomix Sciences, a cutting-edge biotechnology company, has secured a whopping $7.8 million in funding to accelerate the adoption of precision medicine in the treatment of obesity. This influx of capital, including $5.5 million in Series A funding from new investors DexCom, Inc. and Labcorp, along with existing investors like Health2047, is a game-changer in the fight against obesity.
Phenomix's groundbreaking MyPhenome™ test is set to revolutionize the way physicians approach obesity treatment. By identifying specific obesity phenotypes such as Hungry Gut, Hungry Brain, and Emotional Hunger, this test provides crucial insights into why individuals respond differently to various treatments. Co-founders and Mayo Clinic physicians, Andres Acosta, M.D., Ph.D., and Michael Camilleri, M.D., D.Sc., are at the forefront of this innovative approach.
With this funding, Phenomix is poised to expand its portfolio by developing and launching additional phenotyping tests, conducting clinical research, securing patents, and fostering collaborations with pharmaceutical companies and healthcare providers. The company's strategic growth initiatives are paving the way for a future where precision medicine plays a central role in obesity management.
The $2.3 million Phase II Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) further validates Phenomix's commitment to advancing obesity treatment through precision medicine. This grant will support a prospective study to validate the accuracy of the MyPhenome test in predicting responses to obesity treatments, solidifying Phenomix's position as a leader in the field.
Phenomix's recent introduction of the three-in-one MyPhenome obesity phenotyping test is already making waves in the industry, with providers across the United States embracing this innovative approach. Led by CEO Mark Bagnall, Phenomix is at the forefront of a revolution in obesity treatment, where personalized, data-driven solutions are shaping the future of healthcare.
Phenomix's groundbreaking MyPhenome™ test is set to revolutionize the way physicians approach obesity treatment. By identifying specific obesity phenotypes such as Hungry Gut, Hungry Brain, and Emotional Hunger, this test provides crucial insights into why individuals respond differently to various treatments. Co-founders and Mayo Clinic physicians, Andres Acosta, M.D., Ph.D., and Michael Camilleri, M.D., D.Sc., are at the forefront of this innovative approach.
With this funding, Phenomix is poised to expand its portfolio by developing and launching additional phenotyping tests, conducting clinical research, securing patents, and fostering collaborations with pharmaceutical companies and healthcare providers. The company's strategic growth initiatives are paving the way for a future where precision medicine plays a central role in obesity management.
The $2.3 million Phase II Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) further validates Phenomix's commitment to advancing obesity treatment through precision medicine. This grant will support a prospective study to validate the accuracy of the MyPhenome test in predicting responses to obesity treatments, solidifying Phenomix's position as a leader in the field.
Phenomix's recent introduction of the three-in-one MyPhenome obesity phenotyping test is already making waves in the industry, with providers across the United States embracing this innovative approach. Led by CEO Mark Bagnall, Phenomix is at the forefront of a revolution in obesity treatment, where personalized, data-driven solutions are shaping the future of healthcare.